Page 117 - Read Online

Page 14 of 16 Offin et al. J Cancer Metastasis Treat 2023;9:21 https://dx.doi.org/10.20517/2394-4722.2022.140

55. Kindler HL, Novello S, Bearz A, et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive
malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol 2022;23:540-52. DOI PubMed
56. Rottey S, Clarke J, Aung K, et al. Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in
combination with nivolumab in patients with advanced solid tumors. Clin Cancer Res 2022;28:95-105. DOI PubMed
57. Zauderer MG, Offin M. ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma. Lancet Oncol
2022;23:445-6. DOI PubMed
58. Hsu HJ, Tung CP, Yu CM, et al. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with
optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries. Sci Rep 2021;11:15430. DOI PubMed PMC
59. Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, et al. Preclinical efficacy of an antibody-drug conjugate targeting
mesothelin correlates with quantitative 89Zr-ImmunoPET. Mol Cancer Ther 2017;16:134-42. DOI
60. Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: elements and their synergistic function. EBioMedicine 2020;58:102931.
DOI PubMed PMC
61. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic
leukemia. Sci Transl Med 2014;6:224ra25. DOI PubMed
62. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell
malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol
2015;33:540-9. DOI PubMed PMC
63. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med
2013;368:1509-18. DOI PubMed PMC
64. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med
2019;380:1726-37. DOI PubMed
65. Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 2016;6:133-46.
DOI PubMed PMC
66. Chintala NK, Restle D, Quach H, et al. CAR T-cell therapy for pleural mesothelioma: rationale, preclinical development, and clinical
trials. Lung Cancer 2021;157:48-59. DOI PubMed PMC
67. Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent
and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014;6:261ra151. DOI PubMed PMC
68. Tokatlian T, Asuelime GE, Mock JY, et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety
mechanism selectively kills tumor cells. J Immunother Cancer 2022;10:e003826. DOI PubMed PMC
69. Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics 2016;3:16006.
DOI PubMed PMC
70. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor
activity in solid malignancies. Cancer Immunol Res 2014;2:112-20. DOI PubMed PMC
71. Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer
Immunol Res 2013;1:26-31. DOI
72. Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified t cells recognizing
mesothelin in advanced solid cancers. Mol Ther 2019;27:1919-29. DOI PubMed PMC
73. Kiesgen S, Linot C, Quach HT, et al. Abstract LB-378: regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-
intrinsic PD-1 checkpoint blockade: Translation to a phase I trial. Cancer Res 2020;80:LB-378. DOI
74. Annunziata CM, Ghobadi A, Pennella EJ, Vanas J, Powell C, Pavelova M et al. Feasibility and preliminary safety and efficacy of
first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood
mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. In: American Society of Clinical Oncology; 2020.
75. Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with
malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov 2021;11:2748-63. DOI PubMed
PMC
76. TCR Therapeutics. TCR2 therapeutics announces recist responses with first TC-210 dose tested in advanced mesothelin-expressing
solid tumors. Available from: https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-recist-
responses-first-tc-210-dose [Last accessed on 31 May 2023].
77. Obacz J, Yung H, Shamseddin M, et al. Biological basis for novel mesothelioma therapies. Br J Cancer 2021;125:1039-55. DOI
PubMed PMC
78. Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term
survival. Carcinogenesis 2015;36:76-81. DOI PubMed PMC
79. Panou V, Gadiraju M, Wolin A, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J
Clin Oncol 2018;36:2863-71. DOI PubMed
80. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1
losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72. DOI PubMed PMC
81. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5. DOI
PubMed PMC
82. LaFave LM, Béguelin W, Koche R, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med 2015;21:1344-9.